Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review
{{output}}
Background: PARP inhibitors are effective in treating ovarian cancer, especially for BRCA1/2 pathogenic variant carriers and those with HRD (homologous recombination deficiency). Concerns over toxicity and costs have led to the s... ...
